Loxo@Lilly, the oncology unit of US-based Eli Lilly and Company (NYSE: LLY), announced on Friday that the company has received approval for Jaypirca (pirtobrutinib, 100mg & 50mg tablets) from the US Food and Drug Administration.
The product is intended to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) after around two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. It received approval under the FDA's Accelerated Approval pathway based on response rate from the open-label, single-arm, international, Phase one/two study, called the BRUIN trial. Jaypirca received approval based on data from a subset of patients in the BRUIN Phase one/two trial.
Jaypirca is a highly selective kinase inhibitor that uses a novel binding mechanism and is the first and only FDA approved non-covalent (reversible) BTK inhibitor. It can re-establish BTK inhibition in MCL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) and extend the advantage of targeting the BTK pathway.
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
TransCode Therapeutics announces reverse stock split
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management
Nuformix receives positive EMA opinion for orphan drug designation of NXP002 in IPF
Atossa Therapeutics secures new US patent for proprietary (Z)-endoxifen formulations
Myosin Therapeutics receives grant to advance MT-110 clinical trial in methamphetamine use disorder
Bayer launches Phase I trial of targeted alpha therapy for advanced liver cancer
Oramed Pharmaceuticals invests in and collaborates with Alpha Tau Medical